TENAX_RGB.png
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
January 31, 2025 09:00 ET | Tenax Therapeutics
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on...
TENAX_RGB.png
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
January 22, 2025 08:00 ET | Tenax Therapeutics
CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on...
TENAX_RGB.png
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 13, 2024 07:00 ET | Tenax Therapeutics
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative...
TENAX_RGB.png
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
October 31, 2024 16:05 ET | Tenax Therapeutics
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
TENAX_RGB.png
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 13, 2024 16:05 ET | Tenax Therapeutics
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative...
TENAX_RGB.png
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
August 12, 2024 08:00 ET | Tenax Therapeutics
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart...
TENAX_RGB.png
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
August 06, 2024 07:13 ET | Tenax Therapeutics
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on...
TENAX_RGB.png
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024 08:00 ET | Tenax Therapeutics
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF ...
TENAX_RGB.png
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
April 30, 2024 07:30 ET | Tenax Therapeutics
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection...
TENAX_RGB.png
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
April 09, 2024 08:30 ET | Tenax Therapeutics
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction...